NASDAQ:CALA Calithera Biosciences (CALA) Stock Price, News & Analysis → Thousands of investors use this no cost solution | Do you? (From Insider Financial) (Ad) Free CALA Stock Alerts $0.03 0.00 (0.00%) (As of 04/24/2024 ET) Add Compare Share Share Today's Range$0.03▼$0.0350-Day Range$0.02▼$0.0552-Week Range$0.01▼$0.50Volume583 shsAverage Volume1,560 shsMarket Capitalization$141,230.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsFinancialsInsider TradesSEC FilingsSocial MediaSustainabilityStock AnalysisChartCompetitorsFinancialsInsider TradesSEC FilingsSocial MediaSustainability Get Calithera Biosciences alerts: Email Address Ad DTIA new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… Click here to see me place one of these trades LIVE on camera. About Calithera Biosciences Stock (NASDAQ:CALA)Calithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.Read More CALA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CALA Stock News HeadlinesApril 22, 2024 | americanbankingnews.comCalithera Biosciences (NASDAQ:CALA) Research Coverage Started at StockNews.comApril 14, 2024 | americanbankingnews.comCalithera Biosciences (NASDAQ:CALA) Coverage Initiated by Analysts at StockNews.comApril 24, 2024 | DTI (Ad)A new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… February 24, 2024 | uk.investing.comArcus Biosciences Inc (RCUS)August 12, 2023 | npr.orgChristina CalaJune 29, 2023 | seekingalpha.comCalithera Biosciences cancels special meeting due to lack of quorumJune 1, 2023 | finance.yahoo.comCALA - Calithera Biosciences, Inc.May 20, 2023 | finanznachrichten.deCalithera Biosciences, Inc.: Calithera Biosciences Announces Update on Complete Liquidation and DissolutionApril 24, 2024 | DTI (Ad)A new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… May 19, 2023 | travel.usnews.comCala MarioluMay 19, 2023 | seekingalpha.comCalithera Biosciences plans special meeting to seek approval for liquidation and dissolution planMay 19, 2023 | finance.yahoo.comCalithera Biosciences Announces Update on Complete Liquidation and DissolutionMay 13, 2023 | travel.usnews.comCala LlombardsMay 12, 2023 | investing.comCalithera Biosciences Inc (CALA) Earnings Dates & ReportsJanuary 11, 2023 | marketwatch.comCalithera Biosciences Shares Plummet on Liquidation Plans >CALAJanuary 11, 2023 | marketwatch.comCalithera Biosciences to Liquidate >CALAJanuary 10, 2023 | finance.yahoo.comBiotech company Calithera plans its own death. Will others follow?January 9, 2023 | finanznachrichten.deCalithera Biosciences, Inc.: Calithera Biosciences Announces Board Approval of Complete Liquidation and DissolutionJanuary 9, 2023 | markets.businessinsider.comCalithera Biosciences Board Of Directors Determine Dissolution Of CompanyJanuary 9, 2023 | finance.yahoo.comCalithera Biosciences Stock Nosedives On Complete Liquidation, DissolutionJanuary 9, 2023 | finance.yahoo.comCalithera Biosciences Announces Board Approval of Complete Liquidation and DissolutionNovember 15, 2022 | finanznachrichten.deCalithera Biosciences, Inc.: Calithera Biosciences Reports Third Quarter 2022 Financial Results and Business UpdateNovember 15, 2022 | seekingalpha.comCalithera Biosciences, Inc. (CALA) Q3 2022 Earnings Call TranscriptNovember 15, 2022 | finance.yahoo.comCalithera Biosciences Reports Third Quarter 2022 Financial Results and Business UpdateNovember 8, 2022 | finance.yahoo.comCalithera Biosciences to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022October 3, 2022 | marketwatch.comCalithera Biosciences Gets FDA Fast Track For Lung Cancer DrugOctober 3, 2022 | nasdaq.comCalithera Gets FDA Fast Track Designation For Sapanisertib For Squamous Lung Cancer TreatmentSee More Headlines Receive CALA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Calithera Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/08/2021Today4/24/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CALA CUSIPN/A CIK1496671 Webwww.calithera.com Phone(650) 870-1000FaxN/AEmployees8Year Founded2010Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$9.75 million Price / Sales0.01 Cash FlowN/A Price / Cash FlowN/A Book Value($0.40) per share Price / Book-0.07Miscellaneous Outstanding Shares4,870,000Free Float4,550,000Market Cap$141,230.00 OptionableNot Optionable Beta-0.17 Social Links Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMs. Stephanie Wong (Age 50)CFO & Secretary Comp: $752.42kDr. Christopher J. Molineaux Ph.D. (Age 71)Senior Vice President of Development Comp: $405kMr. Frank Parlati Ph.D. (Age 55)Senior Vice President of Research Key CompetitorsScopus BioPharmaNASDAQ:SCPSStatera BiopharmaNASDAQ:STABAthersysNASDAQ:ATHXAptevo TherapeuticsNASDAQ:APVOAmpio PharmaceuticalsNYSE:AMPEView All Competitors CALA Stock Analysis - Frequently Asked Questions How have CALA shares performed in 2024? Calithera Biosciences' stock was trading at $0.03 at the beginning of the year. Since then, CALA shares have decreased by 33.3% and is now trading at $0.02. View the best growth stocks for 2024 here. How were Calithera Biosciences' earnings last quarter? Calithera Biosciences, Inc. (NASDAQ:CALA) announced its earnings results on Monday, November, 8th. The biotechnology company reported ($3.00) EPS for the quarter, topping the consensus estimate of ($4.60) by $1.60. The biotechnology company earned $6.75 million during the quarter. During the same period in the prior year, the firm posted ($6.40) earnings per share. When did Calithera Biosciences' stock split? Calithera Biosciences shares reverse split on Wednesday, June 15th 2022. The 1-20 reverse split was announced on Wednesday, June 15th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, June 15th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Calithera Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Calithera Biosciences investors own include Puma Biotechnology (PBYI), Incyte (INCY), BioMarin Pharmaceutical (BMRN), (MDVN) (MDVN), Celadon Group (CGI), Dynavax Technologies (DVAX), Rigel Pharmaceuticals (RIGL), First Solar (FSLR), Plug Power (PLUG) and Sorrento Therapeutics (SRNE). How do I buy shares of Calithera Biosciences? Shares of CALA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CALA) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThe #1 Crypto for 2024InvestorPlaceDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Calithera Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
